Cambridge Cognition launches web-based testing using digital cognitive markers for virtual neuroscience research

05:00 EST 7 Mar 2017 | BioPortfolio

The neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health worldwide, today announced the launch of a new web-based testing product for conducting academic and clinical research studies online. Disorders affecting the brain are now the leading cause of disability and ill health worldwide. More than 1,000 disorders of the brain and central nervous system (CNS) result in huge costs and more hospitalisations and lost productivity than any other disease group, including heart disease and cancer1.

Advances in research will improve this outlook but administrative costs, inadequate research tools and limited access to patient populations can slow progress. To support neuroscience research, CANTAB Connect, now enables researchers to assess participants on a global scale, in a quick and cost-effective manner. Cambridge Cognition’s CANTAB® technology has been used to measure cognitive function in leading academic and industry research for over 30 years. The Company now markets a range of digital health products on mobile and wearable devices to help recruit participants into clinical trials, validate treatment efficacy and monitor brain health in daily life.

Web-based testing is the latest innovation, empowering researchers to run near-patient testing of participants remotely. The innovation will allow studies to gather digital cognitive biomarkers at frequent time-points for more accurate and rapid data to aid earlier decision-making and conduct large-scale research projects virtually, reducing the overall running costs of studies using proven neuropsychological assessments.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition, commented: “The increasing prevalence of neurological and psychiatric disorders including depression, Parkinson’s and Alzheimer’s disease has resulted in a growing need for innovative neuroscience digital health tools. Web-based testing using CANTAB Connect is a key part of our strategy to provide scientifically proven products to assist researchers and healthcare professionals in improving brain health worldwide.”

For information about web-based cognitive testing:

1Society for Neuroscience. [last accessed 20 February 2017]

About Cambridge Cognition Holdings PLC

Cambridge Cognition is a neuroscience digital health company specialising in the precise measurement of clinical outcomes in neurological disorders. The Company develops and markets validated in-patient assessment software products to improve understanding, diagnosis and treatment in global brain health.

Cambridge Cognition Holdings PLC Steven Powell, Chief Executive Officer Noah Konig, Director of Marketing and Communications Tel: 01223 810 700 finnCap Ltd (NOMAD and Joint Broker) Geoff Nash / Simon Hicks Alice Lane Tel: 020 7220 0500 (Corporate Finance) (Corporate Broking) Dowgate Capital Stockbrokers Limited (Joint Broker) David Poutney / James Serjeant Tel: 01293 517 744 NEXT ARTICLE

More From BioPortfolio on "Cambridge Cognition launches web-based testing using digital cognitive markers for virtual neuroscience research"

Quick Search


Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...